Clostridium Difficile Infection

Clostridium difficile

IDSA Clostridium Difficile Infection GUIDELINES App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/53988

Contents of this Issue

Navigation

Page 3 of 5

Selecting a Treatment Regimen Î Discontinue inciting antimicrobials as soon as possible since this may influence the risk of CDI recurrence (A-II). Î If possible, avoid antiperistaltic agents as they may obscure symptoms and precipitate toxic megacolon (C-III). Î Metronidazole is the drug of choice for the initial episode of mild-moderate CDI. > The dose is 500 mg orally tid for 10-14 days (A-I). Î Vancomycin is the drug of choice for an initial episode of severe CDI. > The dose is 125 mg orally qid for 10-14 days (B-I). Î Vancomycin orally (and per rectum if ileus is present) with or without metronidazole IV is the regimen of choice for the treatment of severe, complicated CDI. > Vancomycin is dosed at 500 mg qid orally and 500 mg in ~100 mL NS q6h retention enema. Metronidazole is given at 500 mg q8h IV (C-III). Î Consider colectomy in severely ill patients. > Monitoring serum lactate and peripheral WBC count may be helpful in prompting a decision to operate since serum lactate rising to 5 mmol/L and WBC rising to 50,000 per mL have been associated with greatly increased peri-operative mortality. If surgical management is necessary, carry out a sub-total colectomy with preservation of the rectum (B-II). Î Treatment of the first recurrence is usually with the same regimen as for the initial episode (A-II) but should be stratified by disease severity (mild to moderate, severe or severe/ complicated) as is recommended for treatment of the initial CDI episode (C-III). Î Do not use metronidazole beyond first recurrence or for long-term chronic therapy due to potential for cumulative neurotoxicity (B-II). Î Treatment of the second or later recurrence with vancomycin using a taper and/or pulse regimen is the preferred next strategy (B-III). Probiotics Î Currently available probiotics are not recommended to prevent primary CDI since there are limited data to support this approach, and there is a potential risk of blood stream infection (C-III). 2

Articles in this issue

Archives of this issue

view archives of Clostridium Difficile Infection - Clostridium difficile